GridAI Technologies Corp.
GridAI Technologies Corp. is a clinical stage biopharmaceutical company, which engages in the research and development of targeted, non-systemic therapies for the treatment of patients with gastrointestinal diseases. Its pipeline includes Latiglutenase, Capeserod, Adrulipase, and Niclosamide. The company was founded on January 30, 2014 and is headquartered in Boca Raton, FL.
| Period | EPS | Revenue | FCF |
|---|---|---|---|
| 2026 Q1 | -0.82 | $38,208 | -$2M |
| 2025 Q4 | -2.92 | $36,251 | -$4M |
| 2025 Q3 | -0.75 | $0 | -$855,688 |
| 2025 Q2 | -0.21 | $0 | -$54,878 |
| 2025 Q1 | -0.28 | $0 | -$818,635 |
| 2024 Q4 | -2.59 | $95,778 | -$171,518 |
| 2024 Q3 |
| -0.59 |
| $0 |
| -$2M |
| 2024 Q2 | -3.86 | $0 | -$3M |